A comprehensive view of Novartis AG. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Transformation & Innovation Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Health Canada approves Novartis’ Tabrecta capmatinib tablets to treat adults with locally advanced unresectable or metastatic non-small cell lung cancer; NSCLC is most common type of lung cancer, will affect 30,000 Canadians in 2022
Published: June 09, 2022 by Canada Newswire
Novartis seeks to grow contract development, manufacturing unit with 15 biotech, cell, gene facilities in US, Europe, Asia; CDMO unit offers microbial fermentation, container filling, global packaging logistics, viral vector production, other services
Published: May 17, 2022 by BioPharma-Reporter.com
Novartis reports combination of Kisqali ribociclib and fulvestrant offer survival benefit of almost 16 months in previously untreated breast cancer versus fulvestrant alone; Kisqali is approved in more than 95 countries to treat breast cancer
Published: May 13, 2022 by SeeNews Pharmaceuticals
Novartis Q1 net profit up 8% from a year ago to US$2.2B, sales up 1% year-over-year to US$12.5B with price erosion, generic competition affecting growth; in-market key growth brands Cosentyx, Entresto, Zolgensma, Kisqali deliver solid growth
Published: May 03, 2022 by SeeNews Pharmaceuticals
Sandoz introduces generic version of AbbVie’s Combigan combination eye drop to treat glaucoma in US in three dosing strengths; Combigan is most-used eye pressure medication, with US sales totaling US$373M in 2021
Published: April 28, 2022 by Indian Pharma Industry : Policies

Ask us about our Transformation & Innovation market view

Trending Chart

Interactive chart with headline count